HSK31858
Phase 3Small molecule
Haisco Pharmaceutical Group Co., Ltd.HSK31858 is one of 182 small molecule programs targeting Tics. It is currently in Phase 3.
6
Indications
11
Total Trials
8
Active Trials
181
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
228 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Lutathera
NovartisPhase 3
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
PLB1004
AAvistone Biotechnology Co., Ltd.
Phase 3
HSK39297
Haisco Pharmaceutical Group Co., Ltd.Phase 3
VDPHL01
VVeradermics, Inc.
Phase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
KN057
SSuzhou Alphamab Co., Ltd.
Phase 3
IN-B00009
HHK inno.N Corporation
Phase 3
QL1206
Qilu Pharmaceutical Co., Ltd.Phase 3
ZM-H1505R
SShanghai Zhimeng Biopharma, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-cystic Fibrosis Bronchiectasis3 trials
Cystic Fibrosis2 trials
Asthma1 trial
Single Ascending Dose1 trial
3 more indications
Tics1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HSK31858. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details